Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma

Bőrgyógyászati és Venerológiai Szemle
doi 10.7188/bvsz.2019.95.3.8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hungarian Dermatological Society

Related search

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

Oncologist
Cancer ResearchMedicineOncology
2019English

Potentials of Brentuximab Vedotin in the Treatment of Relapse/Refractory Cutaneous T-Cell Lymphomas: Literature Review and Authors’ Observation

Vestnik dermatologii i venerologii
2019English

Successful Outcomes of Brentuximab Vedotin Therapy in Recurrent/Refractory Cutaneous T-Cell Lymphomas: Two Case Reports

Immunopathology, Allergology, Infectology
2018English

First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2014English

Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma

OncoTargets and Therapy
OncologyPharmacology
2016English

Prognostic Factors in Patients With Relapsed or Refractory Systemic Anaplastic Large T-Cell Lymphoma (Alcl) Receiving Brentuximab Vedotin and Outcome After Treatment Failure.

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Treatment of Cutaneous T-Cell Lymphoma: An Update

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1993English

Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy